People
At the six-year mark, 90.6% of patients in the Perjeta cohort have not had breast cancer return, compared to 87.8% in the placebo arm. This comes to an absolute benefit of 2.8%.
Dr. Spychala Brings Patient-Centricity and Rare Disease Clinical Research Expertise to New Role
Locana, Inc., a leading RNA-targeting gene therapy company, announced the appointment of James Burns, Ph.D., as chief executive officer, as a key step in expanding the experienced leadership team and as part of a planned transition of the company’s director and recent CEO, Jeffrey M. Ostrove, Ph.D., to continue service as director..
BioArctic AB will be strengthening its management team in 2020 through two strategic recruitments.
Creoptix AG announced the appointment of Line Stigen Raquet as Chief Executive Officer with effect from beginning of January 2020.
“We still have some work in front of us, but we’re happy where we are,” said Jeff Hawkins, CEO of Truvian Sciences.
Despite having one of the best-selling insulin products on the market, Sanofi is exiting diabetes and cardiovascular research and development in favor of more lucrative areas, particularly cancer research.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
Proteona Pte. Ltd. has announced the results of the firstProteona Oncology Challenge, co-sponsored by NovogeneAIT.
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
PRESS RELEASES